$BPTH
BIO-PATH HOLDINGS, INC.

2022 Q4 Form 10-Q Financial Statement

#000155837022017789 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.123M $1.193M $1.088M
YoY Change -7.11% 9.65% 12.16%
% of Gross Profit
Research & Development $2.863M $2.353M $981.0K
YoY Change -1.55% 139.86% -50.95%
% of Gross Profit
Depreciation & Amortization $23.00K $22.00K $20.00K
YoY Change 15.0% 10.0% 100.0%
% of Gross Profit
Operating Expenses $3.986M $3.546M $2.069M
YoY Change -3.18% 71.39% -30.34%
Operating Profit -$3.546M -$2.069M
YoY Change 71.39% -30.34%
Interest Expense $20.00K $11.00K $0.00
YoY Change 1900.0%
% of Operating Profit
Other Income/Expense, Net $11.00K
YoY Change
Pretax Income -$3.966M -$3.535M -$2.069M
YoY Change -3.64% 70.86% -30.34%
Income Tax
% Of Pretax Income
Net Earnings -$3.966M -$3.535M -$2.069M
YoY Change -3.64% 70.86% -30.29%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49 -$0.29
Diluted Earnings Per Share -$0.52 -$0.49 -$294.0K
COMMON SHARES
Basic Shares Outstanding 7.960M 7.160M 6.960M
Diluted Shares Outstanding 7.160M 7.038M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.38M $13.65M $26.60M
YoY Change -56.32% -48.69% 120.57%
Cash & Equivalents $10.38M $13.65M $26.60M
Short-Term Investments
Other Short-Term Assets $1.644M $2.140M $1.519M
YoY Change -10.8% 40.88% -32.79%
Inventory
Prepaid Expenses $3.587M $2.347M $2.113M
Receivables
Other Receivables
Total Short-Term Assets $15.62M $18.14M $30.23M
YoY Change -40.26% -40.01% 111.12%
LONG-TERM ASSETS
Property, Plant & Equipment $158.0K $181.0K $222.0K
YoY Change -29.78% -18.47% -60.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $356.0K $402.0K $447.0K
YoY Change -16.82% -10.07% -18.73%
TOTAL ASSETS
Total Short-Term Assets $15.62M $18.14M $30.23M
Total Long-Term Assets $356.0K $402.0K $447.0K
Total Assets $15.97M $18.54M $30.68M
YoY Change -39.89% -39.57% 106.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $667.0K $1.000M $400.0K
YoY Change 567.0% 150.0% -34.43%
Accrued Expenses $900.0K $1.100M $700.0K
YoY Change 12.5% 57.14% -13.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.684M $2.201M $1.162M
YoY Change 75.78% 89.41% -18.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $113.0K $141.0K $172.0K
YoY Change -26.14% -18.02% -33.85%
Total Long-Term Liabilities $113.0K $141.0K $172.0K
YoY Change -26.14% -18.02% -33.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.684M $2.201M $1.162M
Total Long-Term Liabilities $113.0K $141.0K $172.0K
Total Liabilities $1.797M $2.342M $1.334M
YoY Change 61.75% 75.56% -21.07%
SHAREHOLDERS EQUITY
Retained Earnings -$91.50M -$87.56M -$73.55M
YoY Change 17.82% 19.06%
Common Stock $8.000K $7.000K $7.000K
YoY Change 14.29% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.17M $16.20M $29.35M
YoY Change
Total Liabilities & Shareholders Equity $15.97M $18.54M $30.68M
YoY Change -39.89% -39.57% 106.32%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.966M -$3.535M -$2.069M
YoY Change -3.64% 70.86% -30.29%
Depreciation, Depletion And Amortization $23.00K $22.00K $20.00K
YoY Change 15.0% 10.0% 100.0%
Cash From Operating Activities -$5.000M -$3.374M -$2.891M
YoY Change 78.51% 16.71% 23.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.734M 0.000 1.399M
YoY Change -57900.0% -100.0%
NET CHANGE
Cash From Operating Activities -5.000M -3.374M -2.891M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 1.734M 0.000 1.399M
Net Change In Cash -3.266M -3.374M -1.492M
YoY Change 15.53% 126.14% -36.51%
FREE CASH FLOW
Cash From Operating Activities -$5.000M -$3.374M -$2.891M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$5.000M -$3.374M -$2.891M
YoY Change 79.99% 16.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7038000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7160000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6578000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36333
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0652870
dei Entity Address Address Line1
EntityAddressAddressLine1
4710 Bellaire Boulevard, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Bellaire
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77401
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
742-1357
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BPTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7960164
CY2022Q3 us-gaap Cash
Cash
13650000
CY2021Q4 us-gaap Cash
Cash
23774000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2347000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
523000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2140000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1843000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
18137000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
26140000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1120000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1099000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
939000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
874000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
225000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
221000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203000
CY2022Q3 us-gaap Assets
Assets
18539000
CY2021Q4 us-gaap Assets
Assets
26568000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1046000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
106000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1050000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
770000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2201000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
958000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022Q3 us-gaap Liabilities
Liabilities
2342000
CY2021Q4 us-gaap Liabilities
Liabilities
1111000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
us-gaap Share Based Compensation
ShareBasedCompensation
642000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7160000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7160000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103753000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103111000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87563000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77661000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16197000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18539000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26568000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2353000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
981000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6302000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3002000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1193000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1088000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3613000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3324000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3546000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
2069000
us-gaap Operating Expenses
OperatingExpenses
9915000
us-gaap Operating Expenses
OperatingExpenses
6326000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3546000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2069000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9915000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6326000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2069000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
us-gaap Net Income Loss
NetIncomeLoss
-6324000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7038000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7160000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6578000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
us-gaap Net Income Loss
NetIncomeLoss
-6324000
us-gaap Share Based Compensation
ShareBasedCompensation
591000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
67000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
63000
us-gaap Depreciation
Depreciation
65000
us-gaap Depreciation
Depreciation
56000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1824000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
840000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10103000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7116000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
297000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
591000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1220000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15852000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20009000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
74000
bpth Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
70000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10124000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12846000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13755000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13650000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26601000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
29754000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1399000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
262000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-2069000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
29346000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
19520000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
212000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3535000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16197000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15070000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15852000
bpth Stock Issue During Period Value Warrants Exercised
StockIssueDuringPeriodValueWarrantsExercised
4157000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
591000
us-gaap Net Income Loss
NetIncomeLoss
-6324000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
29346000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25457000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
642000
us-gaap Net Income Loss
NetIncomeLoss
-9902000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
16197000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
500000
CY2022Q3 bpth Expected Advanced Payment To Be Expensed
ExpectedAdvancedPaymentToBeExpensed
2300000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1000000.0
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1100000
CY2022Q3 bpth Accrued Manufacturing And Testing Expenses
AccruedManufacturingAndTestingExpenses
500000
CY2022Q3 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
300000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
100000
CY2022Q3 bpth Accrued Legal And Patent Fees
AccruedLegalAndPatentFees
100000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
800000
CY2021Q4 bpth Accrued Vacation And Bonus
AccruedVacationAndBonus
400000
CY2021Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2021Q4 bpth Accrued Legal And Patent Fees
AccruedLegalAndPatentFees
100000
CY2021Q4 bpth Accrued Manufacturing Expense
AccruedManufacturingExpense
100000
CY2021Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
100000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12200000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0243
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
486000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
192000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
18000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.96
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
658000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.67
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
629000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.96
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
289000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.99
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1500000
bpth Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndUnvestedWeightedAverageRemainingContractualTerm
P2Y4M24D
CY2022Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
5000000.0

Files In Submission

Name View Source Status
0001558370-22-017789-index-headers.html Edgar Link pending
0001558370-22-017789-index.html Edgar Link pending
0001558370-22-017789.txt Edgar Link pending
0001558370-22-017789-xbrl.zip Edgar Link pending
bpth-20220930.xsd Edgar Link pending
bpth-20220930x10q.htm Edgar Link pending
bpth-20220930xex31.htm Edgar Link pending
bpth-20220930xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
bpth-20220930_def.xml Edgar Link unprocessable
bpth-20220930_cal.xml Edgar Link unprocessable
bpth-20220930_pre.xml Edgar Link unprocessable
bpth-20220930x10q_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bpth-20220930_lab.xml Edgar Link unprocessable